References
- Valachis A, Nearchou A. High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis. Acta Oncol Epub 2012 Nov 29.
- Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35:1941–59.
- Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28–38.
- Sasitorn S, Vacharee B, Panya P, Supatporn T, Supot B. Prospective randomized trial for evaluation of efficacy of low versus high dose I-131 for post operative remnant ablation in differentiated thyroid cancer. Chula Med J 2006; 50:695–706.
- Zaman M, Toor R, Kamal S, Maqbool M, Habib S, Niaz K. A randomized clinical trial comparing 50mCi and 100mCi of iodine 131 for ablation of differentiated thyroid cancers. J Pak Med Assoc 2006;56:353–6.
- Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542–6.
- Bal C, Chandra P, Kumar A, Dwivedi S. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer. Nucl Med Commun 2012;33:1039–47.
- Higgins JP, Green S. Investigating heterogeneity in Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. [updated 2011 Mar; cited 2012 Dec 30]. Available from: http://www.cochrane-handbook.org/
- Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: A large randomized clinical trial. Nucl Med Commun 2012;33:275–82.